Lexeo Therapeutics, Inc. Debt Conversion, Converted Instrument, Amount
Lexeo Therapeutics, Inc. (LXEO) reported Debt Conversion, Converted Instrument, Amount of $4.42 million for the 12-month period ending 2023-12-31, per its 10-K filed 2025-03-24.
Financial Statements › Cash Flow › Financing Activities
us-gaap:DebtConversionConvertedInstrumentAmount1 · last filed 2025-03-24
- Lexeo Therapeutics, Inc. debt conversion, converted instrument, amount for fiscal 2023 was $4.42M.
| Period end | Debt Conversion, Converted Instrument, Amount 12 month |
|---|---|
| 2023-12-31 | $4.42M 10-K · filed 2025-03-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| FATE THERAPEUTICS INC (FATE) | United States | $0.280B | -2.51 |
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |